Depression Treatment: Vesicular Signalling and Immune Modulation as Hedonic Fingerprints: Proteomic Profiling in the Chronic Mild Stress Depression Model.
Vesicular signalling and immune modulation as hedonic fingerprints: proteomic profiling in the chronic mild stress depression model.
Filed under: Depression Treatment
J Psychopharmacol. 2012 Nov 8;
Bisgaard CF, Bak S, Christensen T, Jensen ON, Enghild JJ, Wiborg O
Extensive preclinical research has focused at unravelling the underlying molecular mechanisms leading to depression and recovery. In this study, we investigated the quantitative changes in protein abundance in the ventral hippocampal granular cell layer. We compared different phenotypes from the chronic mild stress (CMS) model of depression using chronic administration with two selective serotonin reuptake inhibitors (SSRIs), escitalopram and sertraline. We isolated granular cells using Laser-Capture Microdissection (LCM) and we identified their regulated proteins using two-dimensional (2D) differential gel electrophoresis (DIGE) and tandem mass spectrometry (MS/MS). The majority of the proteins we identified were enzymes involved in different metabolic activities. Additional proteins were functionally classified as vesicular proteins and immune system proteins. Rab GDP dissociation inhibitor alpha (GDIA) and syntaxin-binding protein 1 (STXB1) were potential markers for stress reactivity. Dynamin 1 (DYN1), glutathione S-transferase omega-1 (GSTO1) and peroxiredoxin (PRDX6) were associated with treatment response. In addition, an imbalance between different post-translationally modified versions of DYN1 and GSTO1 potentially accounted for SSRI treatment refraction. In the present study, we searched for new markers of stress reactivity and treatment response as well as any underlying molecular mechanisms correlating to the development of anhedonia and antidepressant therapy refraction. Our results pointed towards an essential role of post-translational modifications in both vesicular and immune protein systems.
HubMed – depression
A novel approach to the diagnosis of stress-induced cardiomyopathy.
Filed under: Depression Treatment
J Am Osteopath Assoc. 2012 Nov; 112(11): 743-7
Haynor J, Colombo C, Javaheri S
Stress-induced cardiomyopathy is becoming a more commonly recognized diagnosis, accounting for 2% to 3% of patients presenting with signs and symptoms of acute anterior myocardial infarction. We present the case of a 68-year-old man with dyspnea 9 days after an unrelated operation. After hospital admission, he complained of chest pain, and an electrocardiogram demonstrated ST-segment elevation in the anterolateral and inferior leads, ST-segment depression in lead aVR, and an absence of ST-segment changes in lead V(1). Cardiac biomarker levels were elevated. Transthoracic echocardiography demonstrated a left ventricular ejection fraction of 30% to 40%, basilar hyperactivity, apical dyskinesia, and distal inferior and anterior akinesia. Cardiac catheterization did not reveal any culprit obstructive lesion. He received a diagnosis of stress-induced cardiomyopathy and was treated according to established recommendations for systolic heart failure. His cardiac biomarkers returned to normal, and a repeated transthoracic echocardiogram 3 days later revealed nearly complete resolution of myocardial wall-motion abnormalities.
HubMed – depression
PATIENT SELF-ASSESSMENT FACTORS PREDICTIVE OF PERSISTENT DEPRESSIVE SYMPTOMS 6 MONTHS AFTER ENROLLMENT IN COLLABORATIVE CARE MANAGEMENT.
Filed under: Depression Treatment
Depress Anxiety. 2012 Nov 8;
Angstman KB, Shippee ND, Maclaughlin KL, Rasmussen NH, Wilkinson JM, Williams MD, Katzelnick DJ
BACKGROUND: Collaborative care management (CCM) is effective for improving depression outcomes. However, a subset of patients will still have symptoms after 6 months. This study sought to determine whether routinely obtained baseline clinical, demographic, and self-assessment variables would predict which patients endorse persistent depressive symptoms (PDS) after 6 months. By estimating the relative risk associated with the patient variables, we aimed to outline the combinations of factors predictive of PDS after CCM enrollment. METHODS: We retrospectively reviewed 1,110 adult primary care patients with the diagnosis of major depressive disorder enrolled in a CCM program and evaluated those with PDS (defined as Patient Health Questionnaire-9score ?10) 6 months after enrollment. RESULTS: At baseline, an increased depression severity, worsening symptoms of generalized anxiety, an abnormal screening on the Mood Disorder Questionnaire (MDQ) and the diagnosis of recurrent episode of depression were independent predictors of PDS. A patient with severe, recurrent depression, an abnormal MDQ screen, and severe anxiety at baseline had a predicted 42.1% probability of PDS at 6 months. In contrast, a patient with a moderate, first episode of depression, normal MDQ screen, and no anxiety symptoms had a low probability of PDS at 6.6%. CONCLUSIONS: This study identified several patient self-assessment scores and clinical diagnosis that markedly predicted the probability of PDS 6 months after diagnosis and enrollment into CCM. Knowledge of these high-risk attributes should alert the clinician to monitor select patients more closely and consider altering therapy appropriately.
HubMed – depression
ABILIFY® (aripiprazole) Add-on Depression Treatment – Treating Major Depression.flv – This is the most current Ability commercial for using Ability in the treatment as an add-on to an antidepressant for treating depression in adults with major depressive disorder. Respective rights go to the makers of Abilify. Please visit my blog @ andysmie.blogspot.com ~ Andy (netsavy006)
Find More Depression Treatment Information…